A Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of FFP104 in the Treatment of Subjects With Moderate to Severely Active Crohn's Disease
Phase of Trial: Phase I/II
Latest Information Update: 03 Mar 2017
At a glance
- Drugs FFP 104 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors FF Pharma
- 07 Jun 2017 Biomarkers information updated
- 23 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 23 Aug 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.